143 related articles for article (PubMed ID: 37400141)
21. Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.
Meng P; Koopman B; Kok K; Ter Elst A; Schuuring E; van Kempen LC; Timens W; Hiltermann TJN; Groen HJM; van den Berg A; van der Wekken AJ
Lung Cancer; 2020 Aug; 146():358-361. PubMed ID: 32534795
[TBL] [Abstract][Full Text] [Related]
22. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
Subbiah V; Kreitman RJ; Wainberg ZA; Cho JY; Schellens JHM; Soria JC; Wen PY; Zielinski C; Cabanillas ME; Urbanowitz G; Mookerjee B; Wang D; Rangwala F; Keam B
J Clin Oncol; 2018 Jan; 36(1):7-13. PubMed ID: 29072975
[TBL] [Abstract][Full Text] [Related]
23.
Sakamoto T; Arai K; Makishima K; Yamasaki A
BMJ Case Rep; 2021 Dec; 14(12):. PubMed ID: 34969785
[TBL] [Abstract][Full Text] [Related]
24. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.
Subbiah V; Kreitman RJ; Wainberg ZA; Cho JY; Schellens JHM; Soria JC; Wen PY; Zielinski CC; Cabanillas ME; Boran A; Ilankumaran P; Burgess P; Romero Salas T; Keam B
Ann Oncol; 2022 Apr; 33(4):406-415. PubMed ID: 35026411
[TBL] [Abstract][Full Text] [Related]
25. BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.
Li J; Wang Q; Ge J; Tian Y; Yao W
Oncologist; 2021 Dec; 26(12):e2115-e2119. PubMed ID: 34516041
[TBL] [Abstract][Full Text] [Related]
26. Vemurafenib Combined With Trametinib Significantly Benefits the Survival of a Patient With Stage IV Pancreatic Ductal Adenocarcinoma With BRAF V600E Mutation: A Case Report.
Wang Z; He D; Chen C; Liu X; Ke N
Front Oncol; 2021; 11():801320. PubMed ID: 35145907
[TBL] [Abstract][Full Text] [Related]
27. MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.
Räsänen K; Dang KX; Mustonen H; Ho TH; Lintula S; Koistinen H; Stenman UH; Haglund C; Stenman J
Mol Oncol; 2018 Feb; 12(2):224-238. PubMed ID: 29193645
[TBL] [Abstract][Full Text] [Related]
28. Molecular Targeting of a BRAF Mutation in Pancreatic Ductal Adenocarcinoma: Case Report and Literature Review.
Seghers AK; Cuyle PJ; Van Cutsem E
Target Oncol; 2020 Jun; 15(3):407-410. PubMed ID: 32495162
[TBL] [Abstract][Full Text] [Related]
29. An advanced pulmonary sarcomatoid carcinoma patient harboring a BRAF
Fang R; Gong J; Liao Z
Front Oncol; 2023; 13():1220745. PubMed ID: 37546400
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients.
Ilie M; Long E; Hofman V; Dadone B; Marquette CH; Mouroux J; Vignaud JM; Begueret H; Merlio JP; Capper D; von Deimling A; Emile JF; Hofman P
Ann Oncol; 2013 Mar; 24(3):742-8. PubMed ID: 23131393
[TBL] [Abstract][Full Text] [Related]
32. Cerebral infarction after treatment with dabrafenib plus trametinib for BRAF-V600E-positive non-small cell lung cancer: A case report.
Taniguchi Y; Tamiya A; Yanagisawa A; Shimaya M; Kawakami M; Inagaki Y; Saijo N; Matsuda Y; Okishio K
Thorac Cancer; 2023 May; 14(13):1201-1203. PubMed ID: 36935386
[TBL] [Abstract][Full Text] [Related]
33. Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report.
Ardalan B; Azqueta JI; England J; Eatz TA
Cold Spring Harb Mol Case Stud; 2021 Oct; 7(5):. PubMed ID: 34667063
[TBL] [Abstract][Full Text] [Related]
34. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
Long GV; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Grob JJ; Chiarion Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JB; Hansson J; Utikal J; Ferraresi V; Kovalenko N; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; DeMarini DJ; Irani JG; Casey M; Ouellet D; Martin AM; Le N; Patel K; Flaherty K
N Engl J Med; 2014 Nov; 371(20):1877-88. PubMed ID: 25265492
[TBL] [Abstract][Full Text] [Related]
35. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
[TBL] [Abstract][Full Text] [Related]
36. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in
Wang JR; Zafereo ME; Dadu R; Ferrarotto R; Busaidy NL; Lu C; Ahmed S; Gule-Monroe MK; Williams MD; Sturgis EM; Goepfert RP; Gross ND; Lai SY; Gunn GB; Phan J; Rosenthal DI; Fuller CD; Morrison WH; Iyer P; Cabanillas ME
Thyroid; 2019 Aug; 29(8):1036-1043. PubMed ID: 31319771
[No Abstract] [Full Text] [Related]
37. Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms.
Elvebakken H; Hjortland GO; Garresori H; Andresen PA; Janssen EAM; Vintermyr OK; Lothe IMB; Sorbye H
J Neuroendocrinol; 2023 Apr; 35(4):e13256. PubMed ID: 37017614
[TBL] [Abstract][Full Text] [Related]
38. BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer.
Ilie MI; Long-Mira E; Hofman V; Mouroux J; Vignaud JM; Gauchotte G; Begueret H; Merlio JP; Emile JF; Hébuterne X; Hofman P
Pathology; 2014 Jun; 46(4):311-5. PubMed ID: 24798160
[TBL] [Abstract][Full Text] [Related]
39. Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer.
Moschetta M; Mak G; Hauser J; Davies C; Uccello M; Arkenau HT
Exp Hematol Oncol; 2017; 6():1. PubMed ID: 28078189
[TBL] [Abstract][Full Text] [Related]
40. Successful BRAF/MEK inhibition in a patient with
Busch E; Kreutzfeldt S; Agaimy A; Mechtersheimer G; Horak P; Brors B; Hutter B; Fröhlich M; Uhrig S; Mayer P; Schröck E; Stenzinger A; Glimm H; Jäger D; Springfeld C; Fröhling S; Zschäbitz S
Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32843432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
